JaredGollobMD
Hematology • Durham, NCspecialization is Internal Medicine - Hematology & Oncology at Duke University Medical Ctr
Are you Dr. Gollob?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 25 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Duke University Medical Ctr
Dumc Box 3441
Durham, NC 27710Phone+1 919-971-1872- Is this information wrong?
Summary
- Dr. Jared Gollob, MD is a hematologist in Durham, North Carolina. He is currently licensed to practice medicine in Massachusetts.
Education & Training
Columbia University Vagelos College of Physicians and SurgeonsClass of 1985
Certifications & Licensure
MA State Medical License 1991 - 2017
Publications & Presentations
PubMed
- 29 citationsA phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David H. Adams, Isabel Conceição, Márcia Waddington-Cruz, Hartmut Schmidt, Juan Buades, Josep M. Campistol, John L. Berk, Michael Polydefkis, Jing Jing ...> ;Orphanet Journal of Rare Diseases. 2020 Jul 8
- 12 citationsDISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis.Ola Akinboboye, Keyur B. Shah, Alberta L. Warner, Thibaud Damy, Herman A. Taylor, Jared Gollob, Christine Powell, Verena Karsten, John Vest, Mathew S. Maurer> ;Amyloid. 2020 May 26
- Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry...Danielle Brandman, Hollis Lin, Anastasia McManus, Sonalee Agarwal, Larry Gache, William Irish, Jared Gollob, Saša A. Živković> ;Progress in Transplantation. 2019 Jun 5
- Join now to see all
Press Mentions
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253May 19th, 2023- Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical TrialsDecember 14th, 2022
- Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual MeetingMay 3rd, 2021
- Join now to see all
